This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Cisco, Sanofi & Charles Schwab
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Sanofi (SNY), and The Charles Schwab Corporation (SCHW).
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Lilly's (LLY) Fifth Tirzepatide Study Meets All Key Endpoints
by Zacks Equity Research
Lilly's (LLY) SURPASS-4 study evaluating tirzepatide against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk meets all primary and key secondary endpoints.
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology
Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts
by Zacks Equity Research
Regeneron (REGN) resumes enrollment in two patient cohorts of pipeline candidate, odronextamab, a CD20xCD3 bispecific antibody, after the FDA lifts partial clinical hold.
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
by Zacks Equity Research
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.
Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response
by Zacks Equity Research
Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.
Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.
Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y
by Zacks Equity Research
Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.
Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales
by Zacks Equity Research
Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.
Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs
by Kinjel Shah
Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.
Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.
BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.
Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View
by Zacks Equity Research
Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.
The Zacks Analyst Blog Highlights: Walmart, Comcast, Broadcom, Sanofi and HSBC Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Comcast, Broadcom, Sanofi and HSBC Holdings
Top Analyst Reports for Walmart, Comcast & Broadcom
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Comcast (CMCSA), and Broadcom (AVGO).
Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe
by Zacks Equity Research
Sanofi's (SNY) new cancer drug, Sarclisa, gets second approval for treating multiple myeloma patients in Europe within a year.
Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development
by Kinjel Shah
FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.